Skip to main content

Table 2 Univariate and multivariate analysis for local control, progression free interval and overall survival according to patient and tumor characteristics

From: Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases

  Univariate Analysis Multivariate Analysis
  HR (CI) p-value HR (CI) p-value
Local control
 Prior Therapy 1.38 (0.36–5.33) 0.642   
 Histology a <0.001 (0-Inf) < 0.001 < 0.001 (0-Inf) 0.998
 GTV Volume b 0.96 (0.90–1.02) 0.163   
 PTV Prescription BED b 0.95 (0.92–0.98) 0.002 0.961 (0.921–1.003) 0.069
 GTV Mean BED b 0.975 (0.954–0.996) 0.011 0.995 (0.973–1.017) 0.664
Progression Free Interval
 Karnofsky Index d 0.51 (0.27–0.98) 0.041 0.81 (0.38–1.73) 0.588
 Gender 0.79 (0.43–1.46) 0.459 n/a n/a
 Age 0.79 (0.43–1.44) 0.435 n/a n/a
 Histology a 1.20 (0.65–2.21) 0.564 n/a n/a
 Prior Therapy 2.10 (1.04–4.23) 0.034 1.57 (0.73–3.37) 0.244
 Extra-hepatic Disease Status c 3.05 (1.59–5.84) 0.000 2.33 (1.07–5.07) 0.033
 Largest GTV Volume b 1.002 (0.998–1.006) 0.283 n/a n/a
 Cumulative GTV Volume b 1.003 (0.999–1.007) 0.110 n/a n/a
 Number of Treated Metastases 1.77 (0.92–3.41) 0.082 1.19 (0.84–1.76) 0.386
Overall Survival
 Karnofsky Index d 0.78 (0.37–1.62) 0.496 n/a n/a
 Gender 0.64 (0.31–1.29) 0.204 n/a n/a
 Age 0.78 (0.38–1.58) 0.483 n/a n/a
 Histology a 0.74 (0.37–1.48) 0.396 n/a n/a
 Prior Therapy 1.86 (0.83–4.17) 0.124 n/a n/a
 Extra-hepatic Disease Status c 2.64 (1.30–5.38) 0.005 2.59 (1.26–5.32) 0.009
 Largest GTV Volume b 1.003 (0.998–1.008) 0.227 n/a n/a
 Cumulative GTV Volume b 1.004 (0.999–1.009) 0.067 1.004 (0.999–1.009) 0.096
 Number of Treated Metastases 1.29 (0.62–2.67) 0.495 n/a n/a
  1. GTV Gross Tumor Volume, PTV Planning Target Volume, BED Biological Effective Dose, HR hazard ratio, CI 95 % confidence interval
  2. a Colorectal Cancer vs. Other Primary Cancer
  3. b Evaluated as Continuous Variables
  4. c No Evidence of Diseases vs. Stable or Progressive Extra-hepatic Diseases
  5. d ≤ 80 % vs. 90–100 %